CN101862326A - Medicine compound containing febuxostat - Google Patents
Medicine compound containing febuxostat Download PDFInfo
- Publication number
- CN101862326A CN101862326A CN200910082252A CN200910082252A CN101862326A CN 101862326 A CN101862326 A CN 101862326A CN 200910082252 A CN200910082252 A CN 200910082252A CN 200910082252 A CN200910082252 A CN 200910082252A CN 101862326 A CN101862326 A CN 101862326A
- Authority
- CN
- China
- Prior art keywords
- febuxostat
- pharmaceutical composition
- preparation
- binding agent
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229960005101 febuxostat Drugs 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 title abstract description 10
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title description 4
- 239000004094 surface-active agent Substances 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000011230 binding agent Substances 0.000 claims description 13
- 239000013078 crystal Substances 0.000 claims description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 5
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 3
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- -1 polyoxyethylene Polymers 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940063451 febuxostat 80 mg Drugs 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 239000000203 mixture Substances 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 238000012856 packing Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 201000005569 Gout Diseases 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 229950005770 hyprolose Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a medicine compound containing febuxostat; and containing the febuxostat and surfactant, the medicine compound can be stably and quickly dissolved out and is applicable to arthrolithiasis curing.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition that contains Febuxostat, be applicable to the too high disease of treatment uric acid.Especially the preparation that utilizes the special additive enhanced stability and prepare with short grained Febuxostat has stable, good dissolution, can guarantee that active component discharges fast fully.
Background technology
Gout is that uric acid is accumulated in vivo owing to produce uric acid in the body and too much reach kidney and remove ability drop, causes urate crystal in the joint and each internal organs precipitation.Clinical treatment gout medicine mainly is divided into the promotion urate excretion and suppresses uricopoiesis at present, and adopts adequate measure to improve related symptoms.Along with the raising of living standards of the people, mainly be that the proportion of various animal foods in dietary structure increases gradually, make original rare gout prevalence grow with each passing day.How to develop a kind of effectively, the medicine of safety and taking convenience become to continue a problem solving.In decades, allopurinol is a unique clinically medicine that is used to suppress uricopoiesis, and be widely used in clinical as the gold medicine of gout, but need repeat heavy dose of administration and keep higher levels of drugs, cause the serious even fatal untoward reaction due to the drug accumulation simultaneously.
Febuxostat (Febuxostat) is novel non-purine class XOR enzyme inhibitor, it has the selectivity of height to XOR, can reduce uricopoiesis, the patient who the overwhelming majority is suffered from gout and hyperuricemia is effective, can make serum uric acid level decline and be stabilized in below the 6.0mg/dl minimizing gouty attack,acute.Febuxostat has very high selectivity, safety and stronger activity than allopurinol.
Yet Febuxostat is an insoluble drug, provides a kind of stable, and the preparation that improves bioavailability is most important.The patent disclosure of CN03806919 a kind of solid preparation that contains single crystal form, mention the most stable crystal formation of use and also can't obtain the little preparation of stripping curve deviation.Difference on the dissolution rate directly causes the time of active component onset.
Therefore, seek valid approach, provide a kind of stable, stripping Febuxostat preparation rapidly is very urgent.
Summary of the invention
The applicant finds can improve its dissolution bioavailability, and obtain good dissolving out capability by reducing the particle diameter of Febuxostat unexpectedly.The applicant finds simultaneously by adding the rapid stripping that a spot of surfactant can make the Febuxostat preparation stabilization.
A kind of pharmaceutical composition that contains Febuxostat contains Febuxostat and surfactant.
Febuxostat is a crystal form in the pharmaceutical composition disclosed by the invention, its X-ray powder diffraction pattern is 6.80 ± 0.2,10.04 ± 0.2,11.00 ± 0.2 at 2 θ, 13.56 ± 0.2,15.72 ± 0.2,17.60 ± 0.2,20.34 ± 0.2,22.08 ± 0.2,23.72 ± 0.2,24.72 ± 0.2,25.34 ± 0.2.
Pharmaceutical composition disclosed by the invention, the particle diameter of Febuxostat (D90) is less than 150 microns.
Pharmaceutical composition disclosed by the invention contains Febuxostat 80mg or 120mg.
Pharmaceutical composition disclosed by the invention further contains one or more pharmaceutically acceptable carriers that are selected from filler, diluent, disintegrating agent, lubricant, binding agent, fluidizer and chelating agen.
Pharmaceutical composition disclosed by the invention, surfactant contain one or more in tween 80, sodium lauryl sulphate, Myrj 52, the polyoxyethylene castor oil glycerin ether.
Pharmaceutical composition disclosed by the invention, surfactant are that the mode with binding agent or wetting agent adds.
Pharmaceutical composition disclosed by the invention is a tablet form.
The specific embodiment
The present invention is described in further detail below in conjunction with embodiment, but be not limited to following embodiment.
Embodiment 1
Preparation method:
30 POVIDONE K 30 BP/USP 30, tween 80 are dissolved in a certain amount of ethanol, as binding agent; With the Febuxostat of recipe quantity and lactose, microcrystalline Cellulose hyprolose, mix the back and add above-mentioned binding agent, stir preparation; Dryly under 40-60 ℃ of temperature conditions must do granule; With dried granule, use the pelletizing machine granulate, and add magnesium stearate, tabletting, 15% Opadry aqueous dispersion coating, packing, promptly.
Embodiment 2
Preparation method:
SDS is dissolved in a certain amount of hot water, adds starch, make 10% starch slurry, as binding agent; With the Febuxostat of recipe quantity and lactose, microcrystalline Cellulose, hyprolose, mix the back and add above-mentioned binding agent, stir preparation; Dryly under 40-60 ℃ of temperature conditions must do granule; With dried granule granulate, and add magnesium stearate, tabletting, 15% Opadry aqueous dispersion coating, packing, promptly.
Embodiment 3
Preparation method:
(Cremophore EL) is dissolved in a certain amount of purified water with the polyoxyethylene castor oil glycerin ether, as wetting agent; With the Febuxostat of recipe quantity and lactose, microcrystalline Cellulose, cross-linked carboxymethyl cellulose sodium, mix the back and add above-mentioned wetting agent, stir preparation; Dryly under 40-60 ℃ of temperature conditions must do granule; With dried granule granulate, and add magnesium stearate, tabletting, 15% Opadry aqueous dispersion coating, packing, promptly.
Embodiment 4
Preparation method:
Myrj 52 is dissolved in a certain amount of purified water, as wetting agent; With the Febuxostat of recipe quantity and lactose, microcrystalline Cellulose, cross-linked carboxymethyl cellulose sodium, mix the back and add above-mentioned wetting agent, stir preparation; Dryly under 40-60 ℃ of temperature conditions must do granule; With dried granule, use the pelletizing machine granulate, and add magnesium stearate, tabletting, 15% Opadry aqueous dispersion coating, packing, promptly.
Annotate: the Febuxostat that uses in the embodiment 1-4 example is the X crystal formation, and through micronization processes, D90 is less than 150 microns.
Embodiment 5
Preparation method:
SDS is dissolved in a certain amount of hot water, adds starch, make 10% starch slurry, as binding agent; With the Febuxostat of recipe quantity and lactose, microcrystalline Cellulose, hyprolose, mix the back and add above-mentioned binding agent, stir and granulate; Dryly under 40-60 ℃ of temperature conditions must do granule; With dried granule granulate, and add magnesium stearate, tabletting, 15% Opadry aqueous dispersion coating, packing, promptly.
Embodiment 6
Preparation method:
Prepare 10% starch slurry, as binding agent; With the Febuxostat of recipe quantity and lactose, microcrystalline Cellulose, hyprolose, SDS, mix the back and add above-mentioned binding agent, stir and granulate; Dryly under 40-60 ℃ of temperature conditions must do granule; With dried granule granulate, and add magnesium stearate, tabletting, 15% Opadry aqueous dispersion coating, packing, promptly.
Embodiment 7
Preparation method:
Prepare 10% starch slurry, as binding agent; With the Febuxostat of recipe quantity and lactose, microcrystalline Cellulose, hyprolose, mix the back and add above-mentioned binding agent, stir and granulate; Dryly under 40-60 ℃ of temperature conditions must do granule; With dried granule granulate, and add magnesium stearate, tabletting, 15% Opadry aqueous dispersion coating, packing, promptly.
Embodiment 8
Embodiment 1-4 and comparative example 1-3 are put under (75% ± 5%, 40 ℃ ± 2 ℃) condition, carry out the preliminarily stabilised investigation, and dissolution when checking 15min (the oar method, 900ml, water, 50 change).The results are shown in following table.
| Dissolution % | 0 day | Quicken January | Quicken February | Quicken March | Quicken June |
| Embodiment 1 | ??96.23±1.04 | ??97.96±2.00 | ??98.08±1.35 | ??99.25±1.43 | ??99.07±1.96 |
| Embodiment 2 | ??98.93±1.10 | ??98.51±1.27 | ??98.93±1.70 | ??99.54±1.29 | ??98.53±1.07 |
| Embodiment 3 | ??97.85±1.38 | ??100.3±1.47 | ??98.27±1.66 | ??98.35±1.89 | ??98.12±1.23 |
| Embodiment 4 | ??99.02±1.57 | ??98.44±2.08 | ??100.0±1.09 | ??98.69±1.76 | ??97.99±1.64 |
| The comparative example 1 | ??78.36±3.06 | ??76.48±5.32 | ??71.65±5.35 | ??68.56±4.14 | ??64.34±5.06 |
| The comparative example 2 | ??73.89±2.88 | ??72.36±3.93 | ??70.84±6.36 | ??63.30±6.26 | ??55.89±4.88 |
| The comparative example 3 | ??65.56±3.62 | ??63.15±4.29 | ??60.97±4.42 | ??54.56±4.61 | ??52.56±5.62 |
Therefore, from the result shown in the table as can be seen, the Febuxostat sheet stripping that compositions of the present invention provides is relatively stable, and rapidly, other every assays prove that also the preparation that is prepared by said composition is very stable simultaneously, are a kind of good preparations therefore.
Claims (7)
1. a pharmaceutical composition that contains Febuxostat is characterized in that containing Febuxostat and surfactant.
2. pharmaceutical composition as claimed in claim 1 is characterized in that described Febuxostat is a crystal form, and its X-ray powder diffraction pattern is 6.80 ± 0.2 at 2 θ, 10.04 ± 0.2,11.00 ± 0.2,13.56 ± 0.2,15.72 ± 0.2,17.60 ± 0.2,20.34 ± 0.2,22.08 ± 0.2,23.72 ± 0.2,24.72 ± 0.2,25.34 ± 0.2.
3. pharmaceutical composition as claimed in claim 1, the particle diameter (D90) that it is characterized in that described Febuxostat is less than 150 microns.
4. pharmaceutical composition as claimed in claim 1 is characterized in that containing Febuxostat 80mg or 120mg.
5. pharmaceutical composition as claimed in claim 1 is characterized in that containing one or more pharmaceutically acceptable carriers that are selected from filler, diluent, disintegrating agent, lubricant, binding agent, fluidizer and chelating agen.
6. pharmaceutical composition as claimed in claim 1 is characterized in that described surfactant is selected from one or more in tween 80, sodium lauryl sulphate, Myrj 52, the polyoxyethylene castor oil glycerin ether.
7. as the described pharmaceutical composition of claim 1-7, it is characterized in that being tablet form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100822522A CN101862326B (en) | 2009-04-20 | 2009-04-20 | Medicine compound containing febuxostat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100822522A CN101862326B (en) | 2009-04-20 | 2009-04-20 | Medicine compound containing febuxostat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101862326A true CN101862326A (en) | 2010-10-20 |
| CN101862326B CN101862326B (en) | 2013-12-04 |
Family
ID=42954387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100822522A Active CN101862326B (en) | 2009-04-20 | 2009-04-20 | Medicine compound containing febuxostat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101862326B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488665A (en) * | 2011-12-15 | 2012-06-13 | 宁夏康亚药业有限公司 | Febuxostat tablet and preparation method thereof |
| CN102614145A (en) * | 2012-04-28 | 2012-08-01 | 杭州朱养心药业有限公司 | Stable febuxostat tablet and preparation method thereof |
| CN102614146A (en) * | 2012-04-28 | 2012-08-01 | 杭州朱养心药业有限公司 | Method for preparing febuxostat tablet and febuxostat tablet |
| CN102895210A (en) * | 2011-12-15 | 2013-01-30 | 宁夏康亚药业有限公司 | Febuxostat tablet with improved dissolution rate |
| CN102895209A (en) * | 2011-12-15 | 2013-01-30 | 宁夏康亚药业有限公司 | Febuxostat tablet |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1954814A (en) * | 2005-10-26 | 2007-05-02 | 重庆医药工业研究院有限责任公司 | Medical composite with co-action for treating gout and its preparation method |
| CN1970547B (en) * | 2006-12-07 | 2011-04-06 | 重庆医药工业研究院有限责任公司 | Novel febuxostat crystal form and its preparation method |
| CN101780073B (en) * | 2009-01-21 | 2013-07-03 | 重庆圣华曦药业股份有限公司 | Febuxostat dispersible tablet drug and preparing method thereof |
-
2009
- 2009-04-20 CN CN2009100822522A patent/CN101862326B/en active Active
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488665A (en) * | 2011-12-15 | 2012-06-13 | 宁夏康亚药业有限公司 | Febuxostat tablet and preparation method thereof |
| CN102895210A (en) * | 2011-12-15 | 2013-01-30 | 宁夏康亚药业有限公司 | Febuxostat tablet with improved dissolution rate |
| CN102895209A (en) * | 2011-12-15 | 2013-01-30 | 宁夏康亚药业有限公司 | Febuxostat tablet |
| CN102895209B (en) * | 2011-12-15 | 2013-12-25 | 宁夏康亚药业有限公司 | Febuxostat tablet |
| CN102895210B (en) * | 2011-12-15 | 2014-08-06 | 宁夏康亚药业有限公司 | Febuxostat tablet with improved dissolution rate |
| CN102614145A (en) * | 2012-04-28 | 2012-08-01 | 杭州朱养心药业有限公司 | Stable febuxostat tablet and preparation method thereof |
| CN102614146A (en) * | 2012-04-28 | 2012-08-01 | 杭州朱养心药业有限公司 | Method for preparing febuxostat tablet and febuxostat tablet |
| CN102614145B (en) * | 2012-04-28 | 2013-05-01 | 杭州朱养心药业有限公司 | Stable febuxostat tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101862326B (en) | 2013-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3417861B1 (en) | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof | |
| JP5282722B2 (en) | Nateglinide-containing preparation | |
| CN100560067C (en) | Hydrochloric acid dronedarone medicinal compositions for oral use and preparation method thereof | |
| TW492878B (en) | Tablet composition | |
| CN101862326B (en) | Medicine compound containing febuxostat | |
| BRPI0713565B1 (en) | process for making a solid oral dosage form | |
| KR101712524B1 (en) | Combinatory formulation comprising tadalafil and dutasteride and the method for preparing thereof | |
| JP6895779B2 (en) | Azilsartan-containing solid pharmaceutical composition | |
| WO2011160541A1 (en) | Tolvaptan solid dispersion and its preparation method | |
| JP2006514100A5 (en) | ||
| CN109692164A (en) | Compound A or the pharmaceutical composition of its salt and preparation method thereof | |
| CN1143908A (en) | Treatment of diabetic nephropathy with valsartan | |
| EP2359816B1 (en) | Aripiprazole formulations | |
| SK2092002A3 (en) | Pharmaceutical agent comprising a benzamide derivative as active ingredient | |
| JP2017523149A (en) | Edoxaban pharmaceutical composition | |
| CN101485659A (en) | Medicament composition of amlodipine and simvastatin as well as preparation method and application thereof | |
| JP2010254580A (en) | Method for producing arginine-containing tablet | |
| EP2925320B1 (en) | Novel method for improving the bioavailability of low aqueous solubility drugs | |
| KR20120118031A (en) | Extended release preparation | |
| CN108714143B (en) | A kind of tablet and preparation method thereof containing Febustat | |
| RU2007147953A (en) | PHARMACEUTICAL RECIPES OF MICRONIZED (4-CHLOROPHENYL) [4- (4-pyridylmethyl) -phthalazin-1-yl] AND ITS SALTS WITH IMMEDIATE EXCESSION AND HIGH CONTENT | |
| EP3154525B1 (en) | Pharmaceutical composition comprising a triazole antifungal agent and method for preparation thereof | |
| CN103458878B (en) | Solid preparation | |
| EP0973508A1 (en) | Pharmaceutical tablet of amiodarone salt | |
| CN101152142A (en) | Solid pharmaceutical composition containing 2-(3-cyano-4- isobutoxy phenyl)-4-methyl-5-thiazole methanoic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210119 Address after: 570314 no.279 Nanhai Avenue, Xiuying District, Haikou City, Hainan Province Patentee after: AVENTIS PHARMA (HAINAN) Co.,Ltd. Address before: 100097, Wanquan mansion, 3 Jin Zhuang, Haidian District, Beijing, Sijiqing Patentee before: BEIJING D-VENTUREPHARM TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Song Xuemei Document name: Notice of conformity |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug combination containing febuxostat Granted publication date: 20131204 Pledgee: Sanya Rural Commercial Bank Co.,Ltd. Pledgor: AVENTIS PHARMA (HAINAN) Co.,Ltd. Registration number: Y2024980014810 |